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Abstract The Human Gene Mutation Database
(HGMD) is a comprehensive collection of germline
mutations in nuclear genes that underlie, or are associated
with, human inherited disease. By June 2013, the database
contained over 141,000 different lesions detected in over
5,700 different genes, with new mutation entries currently
accumulating at a rate exceeding 10,000 per annum.
HGMD was originally established in 1996 for the scientific
study of mutational mechanisms in human genes. However,
it has since acquired a much broader utility as a central
unified disease-oriented mutation repository utilized by
human molecular geneticists, genome scientists, molecular
biologists, clinicians and genetic counsellors as well as by
those specializing in biopharmaceuticals, bioinformatics
and personalized genomics. The public version of HGMD
(http://www.hgmd.org) is freely available to registered
users from academic institutions/non-profit organizations
whilst the subscription version (HGMD Professional) is
available to academic, clinical and commercial users under
license via BIOBASE GmbH.
Introduction
The Human Gene Mutation Database (HGMD) represents
an attempt to collate all known gene lesions responsible for
causing human inherited disease together with disease-
associated/functional polymorphisms that have been pub-
lished in the peer-reviewed literature. These data comprise
single base-pair substitutions in coding, regulatory and
splicing-relevant (both intronic and exonic) regions of
human nuclear genes, as well as micro-deletions and
micro-insertions, combined micro-insertions/micro-dele-
tions (indels) of 20 bp or less, repeat variations, gross
lesions (deletions, insertions and duplications of greater
than 20 bp, up to and including a single characterized gene
or group of contiguous genes that are directly involved in
the aetiology of the disease/phenotype) and complex rear-
rangements (including inversions, translocations and
complex indels). Mutation data are summarized in Table 1.
HGMD does not include either somatic or mitochondrial
mutations, which are well covered by COSMIC (Forbes
et al. 2011) and MitoMap (Ruiz-Pesini et al. 2007),
respectively. HGMD also does not attempt to provide
comprehensive coverage of pharmacological variants
(except for those variants where evidence supporting a
functional impairment has been provided); such variants
are covered by PharmGKB (Thorn et al. 2010). Finally,
HGMD is not a general genetic variation database; users
interested in this type of variant should visit dbSNP (Sherry
et al. 2001) or the Exome Variant Server (http://evs.gs.
washington.edu/EVS/).
HGMD was originally established for the scientific study
of mutational mechanisms in human genes causing inher-
ited disease (Cooper et al. 2010), but has since acquired a
much broader utility as a central unified repository for
germ-line disease-related functional variation. It is now
routinely accessed and utilized by next generation
sequencing (NGS) project researchers, human molecular
geneticists, molecular biologists, clinicians and genetic
counsellors as well as by those specializing in biopharma-
ceuticals, bioinformatics and personalized genomics.
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HGMD is available in two versions: one public, one
obtainable by subscription. The public version of HGMD
(http://www.hgmd.org) is freely available to registered
users from academic institutions/non-profit organizations.
This version is, however, maintained in a basic form that is
only updated twice per annum, is permanently 3 years out
of date, and does not contain any of the additional anno-
tations or extra features present in HGMD Professional
(such as GRCh37/hg19 genomic chromosomal coordinates,
HGVS nomenclature and additional literature references,
see Table 2). The Professional version is available to both
commercial and academic/non-profit users via subscription
from BIOBASE GmbH (http://www.biobase-international.
com).
Acquisition of mutation data
All HGMD mutation data are manually curated from the
scientific literature. Identification of relevant literature
reports is carried out via a combination of manual journal
screening and automated procedures. The database cur-
rently contains mutation entries obtained from over 41,000
primary and 15,000 additional (supplementary) literature
reports published in more than 1,950 different journals. Of
[10,000 identified articles screened for mutation data
during 2012, 35 % contained novel mutation data, 29 %
contained additional useful information (e.g. in vitro
functional data or further clinical or phenotypic informa-
tion) and were therefore cited as additional references,
whilst the remaining 36 % of articles contained no novel
mutation data or supporting information to warrant their
inclusion as either primary or supplementary references in
HGMD. The number of articles screened by HGMD is
increasing on a yearly basis; however, we impose no prior
limit upon the number of articles we include as supple-
mentary references for a given mutation.
For *4 % of all the missense/nonsense mutations
reported in the literature during 2012, it was necessary for
the HGMD Curators to contact the original authors to
obtain correction and/or clarification of the nature or pre-
cise location of the mutations in question. However, only
half of the mutations that required author contact were
satisfactorily resolved by these means, leading to their
inclusion in HGMD; the *2 % of unresolved missense/
nonsense mutations will not be entered into HGMD unless
or until the nature or precise location of the mutation(s) in
question is determined to the satisfaction of the HGMD
curators. Such data (currently 366 entries) are, however,
retained indefinitely by HGMD as part of a ‘‘Bad Bank’’ of
inadequately described mutations.
Classes of variant listed in HGMD
There are six different classes of variant present in HGMD
(Figs. 1, 2). Disease-causing mutations (DM) are entered






Up-to-date mutation data 4 7
Curator comments 4 4
Quarterly updates? 4 7
Gene-oriented search 4 4
Mutation-oriented search 4 7
Reference-oriented search 4 7
Batch search mode 4 7
Chromosomal coordinates 4 7
HGVS nomenclature 4 7
Additional literature references 4 7
Tracked variant history 4 7
dbSNP identifiers 4 7
Enhanced search options 4 7
Advanced search features 4 7
Disease ontology terms* 4 7
Data in VCF* 4 7
Downloadable version 4 7
? HGMD Public is updated on a 6-monthly basis
* Download customers only
Table 1 Numbers of different mutations by mutation type present in
HGMD Professional 2013.2 and the publicly available version of the
database (June 28th 2013)








Missense substitutions 62,368 61,845 44,933
Nonsense substitutions 15,781 15,574 11,306
Splicing substitutions 13,030 12,538 9,467
Regulatory substitutions 2,751 2,713 1,753
Micro-deletions B 20 bp 21,681 21,134 15,796
Micro-insertions B20 bp 8,994 8,721 6,494
Micro-indels B20 bp 2,083 2,004 1,459




Complex rearrangements 1,409 0 946
Repeat variations 421 0 305
Totals 141,161 124,529 99,868
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into HGMD where the authors of the corresponding
report(s) have demonstrated that the reported muta-
tion(s) are involved in conferring the associated clinical
phenotype upon the individuals concerned. The DM clas-
sification may, however, also appear with a question mark
(DM?), denoting a probable/possible pathological muta-
tion, reported to be pathogenic in the corresponding report,
but where (1) the author has indicated that there may be
some degree of uncertainty; (2) the HGMD curators
believe greater interpretational caution is warranted; or (3)
subsequent evidence has appeared in the literature which
has called the putatively deleterious nature of the variant
into question.
Disease-associated polymorphisms (DP) are entered into
HGMD where there is evidence for a significant association
with a disease/clinical phenotype along with additional
evidence that the polymorphism is itself likely to be of
functional relevance (e.g. as a consequence of genic/
genomic location, evolutionary conservation, transcription
factor binding potential, etc.), although there may be no
direct evidence (e.g. from an expression study) of a func-
tional effect. Functional polymorphisms (FP) are included
in HGMD where the reporting authors have shown that the
polymorphism in question exerts a direct functional effect
(e.g. by means of an in vitro reporter gene assay or alter-
natively by protein structure, function or expression stud-
ies), but with no disease association reported as yet.
Disease-associated polymorphisms with supporting func-
tional evidence (DFP) must meet both of the above criteria
in that the polymorphism should not only be reported to be
significantly associated with disease but should also display
evidence of being of direct functional relevance.
Copy number variations (CNVs) represent an important
subset of potentially functional disease-associated varia-
tion. While HGMD does not wish to replicate the excellent
curatorial work of other resources (e.g. the Database of
Genomic Variants http://dgv.tcag.ca/dgv/app/home,
DECIPHER http://decipher.sanger.ac.uk/ and Copy Num-
ber Variation in Disease http://202.97.205.78/CNVD/), we
are nevertheless interested in including such variants (as
gross deletions or duplications) if they meet certain criteria.
Therefore, HGMD will include such variations if they have
been shown to be both of functional significance and
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Fig. 1 5,734 genes are listed in
HGMD professional 2013.2,














































































Fig. 2 HGMD annual mutation
totals subdivided by variant
class. *2013 figures to June 28th
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gene that has itself been directly implicated in the disease
association. Such variants would be entered under one of
the above-mentioned polymorphism categories, depending
upon the supporting evidence provided by the authors of
the original reporting article.
In the opinion of the HGMD curators, the polymorphism
data present in HGMD should be viewed with a consid-
erable degree of caution owing to (1) the possibility that the
observed disease association may be simply due to a
linkage disequilibrium effect rather than a bona fide
underlying functional mechanism and (2) the fact that
in vitro studies are not invariably accurate indicators of
in vivo functionality (Cirulli and Goldstein 2007; Dimas
et al. 2009).
Finally, frameshift or truncating variants (FTV) are
polymorphic or rare variants reported in the literature that
are predicted to truncate or otherwise alter the length of the
gene product (i.e. a stop-gain, stop-loss or frameshift var-
iant) but with no disease association reported as yet. Most
known FTVs have been identified during the course of
large-scale genome/exome screening studies (involving
either patient panels or apparently healthy individuals from
the general population). They may be considered to rep-
resent either latent protein deficiencies or, potentially,
heterozygous carrier states for recessive disorders. Cover-
age of FTVs is far from being comprehensive at this
juncture, and it remains unclear what proportion will turn
out to be clinically significant.
The HGMD curators have adopted a policy of continual
reassessment of the curated content within the database. If
and when additional and important new information per-
taining to a specific mutation entry becomes available (e.g.
questionable pathogenicity, confirmed pathogenicity,
additional clinical or laboratory phenotypes, population
frequency data, supporting functional studies, etc.), then
the mutation entry may be revised or even re-categorized.
Alternatively, a comment or additional reference may be
added in order to communicate this new information to
users. Where new information becomes available which
suggests that a given disease-causing mutation (DM) is
likely to be of questionable pathological relevance or
possibly a neutral polymorphism (on the basis of additional
case reports, genome/population screening studies, pre-
sence in dbSNP with reliable population frequency data,
etc.), it may be flagged with a question mark (DM?) or
even removed from the database entirely if it turns out to
have been erroneously included ab initio. In a recent re-
curation exercise, a total of 539 mutations were re-exam-
ined due to their presence in the 1000 Genomes Project
dataset at a frequency of [1 %. Of the total re-examined,
33 mutations were removed from HGMD, 109 were re-
categorized and 220 had additional comments or references
added to further justify their inclusion in HGMD (Xue et al.
2012). One reason why some HGMD-listed mutations are
often to be found among 1000 Genomes Project data is that
many pathogenic lesions are found quite frequently in the
population at large (Nishiguchi and Rivolta 2012; An-
dreasen et al. 2013; Lazarin et al. 2013; Cooper et al.
2013). In addition to internal curation, users of HGMD
Professional may utilize a feedback function in order to
inform the HGMD curators of relevant new or missing
information, to request corrections or to ask for the
reclassification or removal of a listed variant.
Most of the clinical phenotypes attributed to DMs in
HGMD represent individually rare conditions that are
generally regarded as monogenic diseases. However, it is
important to note that HGMD also considers a few silent
protein deficiencies or biochemical phenotypes (e.g. but-
rylcholinesterase deficiency, reduced oxygen affinity hae-
moglobin, etc.) to be worthy of inclusion since they are
potentially disease-relevant (even if they are relatively
common in the general population); such variants may well
be assigned to the DM category.
For individual mutations in HGMD, the provision of
zygosity information (heterozygous, homozygous or com-
pound heterozygous) has not been attempted. Reasons for
this include (1) the fact that this information is not always
unambiguously provided in the corresponding article; (2)
the possibility that a given mutation may be pathogenic
irrespective of the zygosity in which it is found; (3) the
clinical consequences of zygosity may often be modified
by other genetic variants either in cis or in trans and (4) the
general phenomenon of variable or reduced penetrance
which ensures that the genotype is not invariably predictive
of the phenotype (Cooper et al. 2013). Thus, information
pertaining to zygosity would not always be helpful or
informative with regard to ascertaining or predicting the
clinical phenotype, and indeed might even prove inaccurate
or misleading.
HGMD users should not assume that just because a
mutation is labelled ‘‘DM’’, that it automatically follows
that the mutation is known or believed to be pathogenic in
all individuals harbouring it (i.e. that the mutation exhibits
100 % penetrance). This is not invariably going to be the
case and many ‘‘disease-causing mutations’’ will display
reduced or variable penetrance for a variety of different
reasons (reviewed by Cooper et al. 2013). Indeed, next
generation sequencing programmes (such as the 1000
Genomes Project) are now identifying considerable num-
bers of ‘‘DM’’ mutations in apparently healthy individuals
(MacArthur et al. 2012; Xue et al. 2012). Such lesions
should not automatically be regarded as being clinically
irrelevant because it is quite possible that they represent
low-penetrance, mild or late onset, or more complex dis-
ease susceptibility alleles, as opposed to neutral variants
(Cooper et al. 2013).
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It has always been HGMD policy to enter a variant into
the database even if its pathological relevance may be
questionable (while indicating this fact wherever feasible
to our users), rather than run the risk of inadvertently
excluding a variant that may be directly (or indirectly)
relevant to disease. We have taken several steps to high-
light such equivocation in HGMD, viz. the recent intro-
duction of the DM? variant class, a dbSNP 1000 Genomes
frequency flag (to highlight HGMD variants that are also
present in dbSNP, with allele frequency information
included; see below) and the provision of additional liter-
ature citations where the pathogenicity of the variant may
have been subsequently either questioned or confirmed.
This latter point is particularly pertinent in the clinical
setting, where a greater burden of proof may be required
for use in diagnostic and predictive medicine, and when
considering the return of incidental findings to patients
after testing (Green et al. 2012, 2013; Ng et al. 2013;
Gonsalves et al. 2013).
HGMD Professional
HGMD Professional has been developed to serve as the
subscription version of HGMD, and is available to both
commercial and academic customers under license from
BIOBASE GmbH. HGMD Professional allows access to
up-to-date mutation data with a quarterly release cycle; this
version is therefore essential for checking the novelty of
newly found mutations. HGMD Professional contains
many features not available in the free public version
(Table 2). More powerful search tools in the form of an
expanded search engine with full text Boolean searching
are provided. A batch search mode has recently been
developed to allow users to search HGMD using gene (e.g.
OMIM IDs) and variant (e.g. dbSNP IDs) oriented lists.
Users can employ these tools to perform additional sear-
ches for gene-specific (e.g. chromosomal locations, gene
names/aliases and gene ontology), mutation-specific (e.g.
chromosomal coordinates, HGVS nomenclature, dbSNP
ID) or citation-specific (e.g. first author, publication year,
PubMed ID) information. The provision of chromosomal
coordinates (hg19) for the vast majority of our nucleotide
substitutions (98.7 % coverage) and other micro-lesions
(97.3 % coverage) has made HGMD an invaluable tool for
the large-scale analysis of NGS datasets such as the 1000
Genomes Project (1000 Genomes Project Consortium
2010, 2012). Additional information is also provided on a
mutation-specific basis including curatorial comments
pertaining to particular mutations (for example, if the
mutation data presented required in-house correction in
relation to the data presented in the original publication
[5–10 % of entries], or if the clinical phenotype is
associated with a more complex, i.e. a digenic or SNP in-
cis inheritance pattern), additional reports comprising
functional characterisation, further phenotypic information,
comparative biochemical parameters, evolutionary con-
servation and SIFT (Sim et al. 2012) and MutPred (Li
et al., 2009) predictions. These additional annotations are
updated on a regular basis.
Recently, HGMD clinical phenotypes have been anno-
tated against the Unified Medical Language System
(UMLS) using a combination of manual curation and nat-
ural language processing. The UMLS is a comprehensive
collection of biomedical concepts and the relationships
between them (http://www.nlm.nih.gov/research/umls/).
These UMLS mappings provide users with a more accurate
and expanded phenotype search. Thus, searches using
alternative disease names will return the same result-set,
e.g. a search for ‘‘breast cancer’’ would yield identical
results to a search for ‘‘malignant breast tumour’’. In
addition, utilizing the UMLS allows for powerful semantic
searching (e.g. searches for all mutations linked to blood
disorders or all immune disorders).
Another new feature involves the highlighting of
HGMD entries where the pathogenicity of the variant may
have been cast into doubt by virtue of its allele frequency.
HGMD Professional now displays a frequency flag when a
listed variant is also found in dbSNP, and population fre-
quency data from the 1000 Genomes Project are also
provided. HGMD data have also recently been made
available in Variant Call Format or VCF (Danecek et al.
2011), which will facilitate the comparison of HGMD with
large NGS datasets. In addition to searching and viewing
mutation data in a variety of ways, users of HGMD Pro-
fessional may utilize a new feedback facility to submit
corrections to the database curators or to request additional
features.
HGMD Professional also contains an Advanced Search
suite which has been designed to enhance mutation
searching, viewing and retrieval. Two of the main types of
mutation in HGMD (single-nucleotide substitutions and
micro-lesions) can be interrogated with this toolset. Data-
sets for more than one mutation type may be combined (for
example, micro-deletions, micro-insertions and indels) to
enable more powerful searching across comparable types
of mutation. When using the Advanced Search, users can
tailor their queries with more specific criteria, including
functional profile (e.g. in vitro and in silico characterized
transcription factor binding sites, post-translational modi-
fications, microRNA binding sites, upstream ORFs, and
catalytic residues, see Fig. 3); amino-acid change; nucle-
otide substitution; size and/or sequence composition of
micro-deletions, micro-insertions or indels; pre- or user-
defined sequence motifs (both those created and those
abolished by the mutation); dbSNP number; keywords
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found in the article title or abstract. Results returned by the
Advanced Search can be downloaded as tab-delimited text
or a genome browser track, ready to be used in different
applications. The Advanced Search also includes a batch
mode called ‘‘Mutation Mart’’ to query HGMD via multi-
ple identifiers including dbSNP, Entrez gene (http://www.
ncbi.nlm.nih.gov/gene) and PubMed. HGMD Professional
is available to subscribers either as an online only package
or in downloadable form enabling users to incorporate
HGMD data into their local variant analysis pipelines
(http://www.biobase-international.com).
Other variant databases
Several other databases are available that attempt to record
disease-causing or disease-associated (i.e. pathogenic)
variation. These include the Online Mendelian Inheritance
in Man, OMIM (http://www.omim.org/; Amberger et al.
2009), ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/),
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/; Sherry et al.
2001) and an assorted collection of locus-specific mutation
databases (LSDBs) (http://www.hgvs.org/dblist/glsdb.
html). OMIM does not provide statistics for allelic vari-
ants on its website; however, 22,901 germline OMIM
variants appear to have been added to ClinVar, which itself
contains a total of 25,375 pathogenic and probable patho-
genic germline variants, while dbSNP contains 23,973
pathogenic or probable pathogenic germline variants (all
databases were accessed July 10th 2013). Owing to the
highly dispersed nature of the LSDBs and the potential for
duplication between databases, accurate statistics with
regard to like-for-like bona fide germline disease-causing
(not merely neutral) variation is difficult to obtain. Since
OMIM only records a limited number of variants per gene,
and ClinVar is still in its infancy, HGMD is the only
database of human pathological mutations that approaches
comprehensive coverage of the peer-reviewed literature
(Peterson et al. 2013). Since ClinVar and the LSDBs
contain unpublished (non-peer reviewed) mutation data,
the question has arisen as to whether HGMD should also
include these data (Patrinos et al. 2012). However, several
obstacles have been encountered by the LSDBs, including
serious problems pertaining to data quality as well as issues
of data provenance and consent. HGMD has therefore
taken the decision not to include such data at this time.
Fig. 3 Advanced nucleotide substitutions search in HGMD Professional
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How HGMD is utilized
Registered users of the public HGMD website currently
number in excess of 60,000. Users may not download
HGMD data in their entirety. However, mutation data may
be made available at the discretion of the curators for non-
commercial research purposes. Potential collaborators who
wish to access HGMD data in full are required to sign a
confidentiality agreement.
HGMD data have been used to perform an extensive series
of meta-analyses on different types of gene mutation causing
human inherited disease. These studies have helped to
improve our understanding of mutational spectra and the
molecular mechanisms underlying human inherited disease
(Cooper et al. 2011). They have served to demonstrate not
only that human gene mutation is an inherently non-random
process but also that the nature, location and frequency of
different types of mutation are shaped in large part by the local
DNA sequence environment (Cooper et al. 2011). HGMD
data have been used extensively in several international col-
laborative research projects including the 1000 Genomes
Project (1000 Genomes Project 2010, 2012), where a sur-
prising number of HGMD variants were found in apparently
healthy individuals. They have also been used in the com-
parative analysis of several orthologous genomes including
gorilla (Scally et al. 2012), cynomolgus and Chinese macaque
(Yan et al. 2011), Rhesus macaque (Rhesus Macaque Genome
Sequencing and Analysis Consortium 2007) and rat (Rat
Genome Sequencing Project Consortium 2004), in which
many apparently disease-causing mutations in human were
found as wild type (‘compensated mutations’).
In a clinical setting, HGMD is widely utilized by many
groups in ongoing NGS diagnostic (Johnston et al. 2012,
Calvo et al. 2012, Bell et al. 2011) and human genome
sequencing (Tong et al. 2010; Kim et al. 2009) pro-
grammes. HGMD has also been used by a number of dif-
ferent groups to aid the development of post-NGS variant
interpretation algorithms including MutPred (Li et al.
2009), PROVEAN (Choi et al. 2012), CAROL (Lopes et al.
2012), CRAVAT (Douville et al. 2013), NEST (Carter
et al. 2013) and FATHMM (Shihab et al. 2013). Finally,
HGMD has been used as a resource for structural biologists
in the reconstruction of protein interaction networks (Wang
et al. 2012; Guo et al. 2013). A more complete list of
articles which have utilized HGMD data or expertise in
their production can be found on the HGMD website
(http://www.hgmd.cf.ac.uk/docs/articles.html).
Data sharing
A limited HGMD data set, containing both chromosomal
coordinates and HGMD identifiers, has been made available
via academic data exchange programmes to the Gen2Phen
project (Webb et al. 2011), the European Bioinformatics
Institute (EBI)/Ensembl (Flicek et al. 2013) and the Uni-
versity of California, Santa Cruz (UCSC) (Meyer et al. 2013)
and may be viewed in these projects’ respective genome
browsers. Data from HGMD Professional have additionally
been made available to HGMD subscribers via Genome
TraxTM (BIOBASE GmbH) and Alamut (Interactive Bio-
software), but are also accessible as part of the HGMD
Professional stand-alone package (BIOBASE GmbH).
Allowing free access to the bulk of the mutation data present
in HGMD, while generating sufficient income from its
commercial distribution to support its maintenance and
expansion, represents a business model that should maxi-
mize the availability of HGMD at the same time as ensuring
its long-term sustainability. Although we are necessarily
obliged to be prudent with regard to data sharing with public
data repositories, we have always taken the view that making
as much data as possible publicly available is generally
beneficial to both HGMD and its users worldwide.
Future plans
The provision of chromosomal coordinates for the vast
majority of coding region micro-lesions in HGMD is now
complete. Expanding this provision to include micro-
lesions in non-coding regions and the gross and complex
lesion dataset (where feasible) is a high priority, as is
expanding the provision of genomic coordinates to include
popularly utilized NGS formats such as General Feature
Format (GFF) (http://www.sanger.ac.uk/resources/
software/gff/) and BED format, to complement the
recently added HGMD Variant Call Format (VCF)
(Danecek et al. 2011). Mutations will also be mapped to the
new genome build (GRCh38) in due course. A listing of
removed variants will be implemented as time allows.
Provision of genomic reference sequences based on the
NCBI RefSeqGene project (Pruitt et al. 2009), links to
available protein structures and homology models, and
mapping HGMD phenotypes to the Human Phenotype
Ontology (HPO) are also regarded as priorities.
In its current state of development, HGMD provides the
user with a unique resource that can be utilized not only to
obtain evidence to support the pathological authenticity and/
or novelty of detected gene lesions and to acquire an overview
of the mutational spectra for specific genes, but also as a
knowledgebase for use in the bioinformatics and whole gen-
ome screening projects that underpin personalized genomics.
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